Literature DB >> 1342634

Discounting and health benefits: another perspective.

J Cairns1.   

Abstract

This paper reviews the argument advanced by Parsonage and Neuburger that the non-monetary benefits of health programmes should be discounted at a lower rate than that used for financial flows. The conceptual issues raised in that paper are discussed and others, such as the tradability of non-monetary benefits and the link between individual and social discount rates, are introduced. The collection and assessment of more evidence is needed before Parsonage and Neuburger's proposition can be supported.

Mesh:

Year:  1992        PMID: 1342634     DOI: 10.1002/hec.4730010111

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  20 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

3.  Health economic evaluation.

Authors:  A Shiell; C Donaldson; C Mitton; G Currie
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

Review 4.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 5.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 6.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Regulation of the pharmaceutical industry and now pharmacoeconomic research?

Authors:  N E Wells
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

8.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

9.  Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

Authors:  D Coyle; K Tolley
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

10.  An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.

Authors:  S Hummel; J Piercy; R Wright; A Davie; A Bagust; J McMurray
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.